Randomized Clinical Trial, conventional treatment-controlled, studying the efficacy of Plasma Rich in Growth Factor (PRGF®) in alveolar ridge preservation after simple exodontia in the anterior region of maxilla.

BTI I MAS D0 个研究点目标入组 62 人开始时间: 2019年6月11日最近更新: 2019年12月10日

试验速览

暂无简介。

•- Subjects of both sexes with an age greater than or equal to 18 years.
•- Clinical indication for a simple exodontia of a uniradicular tooth in the superior maxilla
•- Availability to follow-up during the treatment period
•- Subjects with non-active periodontal disease.
•- Buccal dehiscence < than 25% in the vestibular table
•- Signing the informed content
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 56
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 6

•Presence of an active infection
•- Loss of any plate of the socket
•- Severe inflammation in the area of the exodontia previous to the intervention
•- Suffer any severe hematologic disease o disorder
•- Have received radiotherapy, chemotherapy or immunosuppressive treatments, systemic corticosteroids and/or anticoagulants the 30 days prior to inclusion
•- Regular treatment with AINES or other antiinflammatory drugs
•- Previous history of chronic hepatitis or heatic cirrhosis
•- Uncontrolled diabetes mellitus (Glycosylated hemoglobin higher than 9%)
•- Subjects submitted to hemodyalisis
•- Presence of malignant tumour, haemangiomas or angioma in the exodontia region.
•- Previous history of ischemic cardiopathy in the last year.
•- Pregnancy or womens in childbearing age who do not take contraception measures.
•- Nursing womens
•- Metabolic bone disease
•- Ongoing treatment with biphosphonates both through oral or intravenous administration
•- Smoking habits (> 10 cigarrettes/day)
•- In general, any disability to participate in the study

发起方

BTI I MAS D